Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



January 2005, Volume 35 Number 1 , p 29 - 29



© 2005 Lippincott Williams & Wilkins, Inc. Volume 35(1)             January 2005             p 29 Docetaxel approved for prostate cancer [DRUG NEWS: BREAST CANCER DRUG]

A mainstay for breast cancer treatment, docetaxel (Taxotere) has been approved by the FDA to treat prostate cancer too.

Given by injection in a regimen that includes prednisone, the drug may prolong the lives of men with advanced disease. In clinical trials, the treatment extended life for men with metastatic, hormone-refractory prostate cancer by about 2½ months, compared with a similar group receiving standard chemotherapy with mitoxantrone and prednisone.

Patients receive a docetaxel injection once every 3 weeks and prednisone daily. Possible adverse reactions include nausea, alopecia, bone marrow suppression, fluid retention, and peripheral neuropathy.

For more information, visit the FDA's Web site ...

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: